StreetAlpha.app
Home › Stocks › HRMY

Harmony Biosciences Holdings, Inc. (HRMY)

Healthcare
$33.01
▲ +0.15%
LAST CLOSE · NOV 17

Harmony Biosciences develops and sells WAKIX for narcolepsy and other treatments for rare neurological diseases. It last closed at $33.01 on Nov 17, up 0.15% on the day.

AI Auto Pilots
Is HRMY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$989.4M
+19.8% vs a year ago
Net income
$178.6M
−3.8% vs a year ago
EPS (diluted)
$3.02
−4.7% vs a year ago
Gross margin
74.0%
$732.4M gross profit
Valuation
Market cap
$1.9B
58.7M shares
P/E
10.9
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$647.1M
At Sep 30
Debt
$149.1M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
58.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $305.4M$305.4MFY2021FY2022: $437.9M$437.9MFY2022FY2023: $582.0M$582.0MFY2023FY2024: $714.7M$714.7MFY2024FY2025: $868.5M$868.5MFY2025

From HRMY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated HRMY in the past 90 days, not enough for a consensus
Average 12-month target
$60.00
▲ 81.8% upside

Based on 1 analyst who set a price target on HRMY in the past 90 days. The average target is $60.00, with a high of $60.00 and a low of $60.00, compared with the last close of $33.01.

Low $60.00Avg $60.00High $60.00
Blue marker: last close $33.01
Highest target$60.00
Average target$60.00
Lowest target$60.00
Latest rating changes
Wolfe ResearchInitiated
Aug 26Buy$60
Truist SecuritiesMaintained
Aug 5Hold$34
NeedhamMaintained
Aug 4Buy$50
MizuhoMaintained
Jul 31Buy$51
HC Wainwright & Co.Reiterated
Jul 16Buy$55
DateFirmActionRatingPrice target
Aug 26Wolfe ResearchInitiatedBuy$60
Aug 5Truist SecuritiesMaintainedHold$34
Aug 4NeedhamMaintainedBuy$50
Jul 31MizuhoMaintainedBuy$51
Jul 16HC Wainwright & Co.ReiteratedBuy$55
Loading…

Technical Analysis

HRMY · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 8% below its 20 day and 16% below its 50 day average. It is 5% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot at $32.94, and the nearest resistance the Pivot R1 at $33.36.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 4.6%/day
Key levels
$43.4952 week high+31.7%
$38.2850 day average+16.0%
$37.99100 day average+15.1%
$35.5620 day average+7.7%
$34.53200 day average+4.6%
$34.38Swing high (Nov 11)+4.2%
$33.36Pivot R1+1.1%
$33.01Last close
$32.94Pivot−0.2%
$32.59Pivot S1−1.3%
$32.27Swing low (Nov 6)−2.2%
$25.9052 week low−21.5%
Indicators
RSI (14)33.89Weak, oversold below 30Neutral
MACD-1.48Below its signal lineBearish
Stochastic14.1Near the bottom of its rangeOversold
ADX (14)36.1Trending down
Williams %R-89.3Oversold below −80, overbought above −20Oversold
CCI (20)-85.5Oversold below −100, overbought above 100Neutral
Rate of change−10.8%Change over 10 sessionsBearish
ATR (14)$1.51Typical daily range, 4.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HRMY

What happened before

See how HRMY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow HRMY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HRMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in HRMY in the last 90 days.

Loading…

See today’s whale options flow across the market →

HRMY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲235 buying vs 110 selling
  • ▲Held by funds +4.4 pts
  • ▲Funds holding +31
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding358327+9.5%
In funds' top 1032+50.0%
Held by funds96.7%92.3%+4.4 pts
New / increased63 / 17250 / 131+29.8%
Reduced / sold out76 / 34107 / 33−21.4%
Put/call ratio5.15––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HRMY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HRMY is in one of them and how their past HRMY trades turned out.

HRMY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HRMY in an article yet. Here's the latest on the wider market.

About Harmony Biosciences Holdings

Harmony Biosciences is a neuroscience company based in Plymouth Meeting, Pennsylvania, that focuses on rare neurological diseases. Its main product, WAKIX, is a prescription tablet taken once a day to treat excessive daytime sleepiness and cataplexy in people with narcolepsy. The company is also developing treatments for other rare conditions, including certain epilepsy syndromes. Healthcare providers prescribe its medicines to patients.

Headquarters
Plymouth Meeting, PA